Daily Guru Alerts
- Dylan Jovine
- Tuesday, September 19, 2023
The company has strong technology…made even stronger by the fact that NVIDIA invested $50 million in them this past July
- Dylan Jovine
- Wednesday, June 14, 2023
Let's start by closing out one of our older positions for a small profit.
- Dylan Jovine
- Monday, June 5, 2023
ImmunoGen Inc. (SYM:IMGN) added 17% pre-market this morning to $16.50, a 211% gain from our recommended price of $5.30.
- Dylan Jovine
- Wednesday, May 3, 2023
Shares of one of ImmunoGen (SYM: IMGN) are up 100% today after the company posted great Phase 3 trial results for its ovarian cancer drug, Elahere.
- Dylan Jovine
- Friday, January 13, 2023
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
- Dylan Jovine
- Friday, July 15, 2022
For 40 years, ImmunoGen has been targeting a better life for people with cancer, as they believe it’s not enough to disrupt the progress of the disease, they want to keep cancer from disrupting someone's life.
- Dylan Jovine
- Tuesday, September 19, 2023
The company has strong technology…made even stronger by the fact that NVIDIA invested $50 million in them this past July
- Dylan Jovine
- Wednesday, June 14, 2023
Let's start by closing out one of our older positions for a small profit.
- Dylan Jovine
- Monday, June 5, 2023
ImmunoGen Inc. (SYM:IMGN) added 17% pre-market this morning to $16.50, a 211% gain from our recommended price of $5.30.
- Dylan Jovine
- Wednesday, May 3, 2023
Shares of one of ImmunoGen (SYM: IMGN) are up 100% today after the company posted great Phase 3 trial results for its ovarian cancer drug, Elahere.
- Dylan Jovine
- Friday, January 13, 2023
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
- Dylan Jovine
- Friday, July 15, 2022
For 40 years, ImmunoGen has been targeting a better life for people with cancer, as they believe it’s not enough to disrupt the progress of the disease, they want to keep cancer from disrupting someone's life.
deal of the month
Categories
A Warning for US Investors #shorts
Protecting Your Portfolio from the Rise of China #shorts
US Military LOSES in Simulated War Games Against China #shorts
Recent posts
Tags
Connect with Us
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.
